Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (321-330 of 539) with videos related to

Pageof 54
Sort By:
Blood Cancer Journal|June 19, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myelomaSundar Jagannath, Yi Lin, Hartmut Goldschmidt, et al.
Leukemia|February 10, 2019
Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myelomaHauke Thomsen, Subhayan Chattopadhyay, Niels Weinhold, et al.
British Journal of Haematology|April 27, 2011
Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histologyJens Hillengass, Tobias Bäuerle, Reiner Bartl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy A Brighton, Amit Khot, Simon J Harrison, et al.
Blood|February 21, 2009
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorAnne Catherine Sprynski, Dirk Hose, Laurent Caillot, et al.
Blood|September 3, 2015
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging SystemRowan Kuiper, Mark van Duin, Martin H van Vliet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myelomaDavid C Johnson, Sophie L Corthals, Brian A Walker, et al.
British Journal of Haematology|March 19, 2016
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trialElias K Mai, Axel Benner, Uta Bertsch, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 3, 2026
Interpreting [<sup>18</sup>F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trialChristos Sachpekidis, Marina Hajiyianni, Markus Wennmann, et al.
Pageof 54

Showing results (321-330 of 539) with videos related to

Sort By:
Pageof 54
Blood Cancer Journal|June 19, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myelomaSundar Jagannath, Yi Lin, Hartmut Goldschmidt, et al.
Leukemia|February 10, 2019
Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myelomaHauke Thomsen, Subhayan Chattopadhyay, Niels Weinhold, et al.
British Journal of Haematology|April 27, 2011
Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histologyJens Hillengass, Tobias Bäuerle, Reiner Bartl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy A Brighton, Amit Khot, Simon J Harrison, et al.
Blood|February 21, 2009
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorAnne Catherine Sprynski, Dirk Hose, Laurent Caillot, et al.
Blood|September 3, 2015
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging SystemRowan Kuiper, Mark van Duin, Martin H van Vliet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myelomaDavid C Johnson, Sophie L Corthals, Brian A Walker, et al.
British Journal of Haematology|March 19, 2016
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trialElias K Mai, Axel Benner, Uta Bertsch, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 3, 2026
Interpreting [<sup>18</sup>F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trialChristos Sachpekidis, Marina Hajiyianni, Markus Wennmann, et al.
Pageof 54